Compare Jumia Technologies AG - ADR (JMIA) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Mesoblast Limited — how do they compare? Jumia Technologies AG - ADR trades at $6.4 (market cap $865.90M), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 2× Jumia Technologies AG - ADR's market cap, and Mesoblast Limited is more actively traded (239,027 versus 1,695,227). Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 28 Days and Mesoblast Limited for 15 Days on average.
| JMIA | MESO | |
|---|---|---|
Market Cap | $865.90M | $1.75B |
Volume | 1,695,227 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $20.96 |
52-Week Low | $5.69 | $13.19 |
Typical Hold Time | 28 Days | 15 Days |
Enterprise Value | $831.54M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA stock trades at $6.28, down 6.82% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $167M in 2024 to $189M in 2025 and narrowing losses. Analyst consensus remains strong with 71% buy ratings and a $12.00 price target, supported by recent $50M capital infusion and path to EBITDA breakeven.
The outlook suggests potential upside if JMIA achieves profitability targets, but risks include persistent negative margins, high P/B ratio of 975, and competitive pressures in African e-commerce. The stock offers speculative growth potential with significant execution risk.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
